Navigation Links
Mirixa Australia Achieves Six Month Milestones
Date:11/17/2009

RESTON, Va. and SYDNEY, Nov. 17 /PRNewswire/ -- Mirixa Corporation, the leader in pharmacy-based patient care services and the Pharmacy Guild of Australia, the peak body representing owners of pharmacies across Australia, announced today results of the first six months of operating activity of Mirixa Australia.

In less than two full quarters of operation, Mirixa Australia has successfully engaged over 40% of all pharmacies nationwide, enabling the delivery of patient care services via the customized Australian version of the MirixaPro(SM) clinical platform.

Mirixa Australia, a subsidiary of the Pharmacy Guild of Australia, now operates patient medication adherence programs, delivered person-to-person at community pharmacy, for both brand and generic medications. Current Australian programs include GSK's Seretide, Pfizer's Lipitor, and generic simvastatin, pravastatin, omeprazole and sertraline medicines offered by Australia's three largest generic medicine distributors, namely Alphapharm, Apotex and Sigma. Programs generally target those patients whose MedsIndex score falls below 70 - an indicator of sub-optimal adherence. The Pharmacy Guild of Australia created and introduced MedsIndex in 2007, and with the help of the Mirixa U.S. team, integrated this score into programs offered through the MirixaPro clinical platform in Australia.

"We're quite proud of what our Australian pharmacy colleagues have accomplished over a very short span of time," said Rick Solano, President and Chief Executive Officer of Mirixa. "The growth rate achieved by Mirixa Australia and its pharmacy partners is truly impressive. They are well on their way to establishing a national pharmacy network to deliver meaningful patient care services similar to what we've achieved here in the U.S.," added Mr. Solano.

Analysis of data by Mirixa Australia across all programs for one of its pilot network pharmacies revealed that after only 12 weeks of program implementation, over 60% of patients had an improvement in medication adherence as measured by their MedsIndex score, and the average adherence improvement across all enrolled patients exceeded 25 percent.

"Medication non-adherence both here in Australia and worldwide represents a key source of both excess cost and suboptimal health outcomes," noted Kos Sclavos, National President of the Pharmacy Guild of Australia. "While we're still early in the game, we're very pleased with the results we're seeing. We have been waiting to see the 12 week result which coincides with the second patient consultation and these results exceed our expectation. The MedsIndex trend measured thus far encourages us that we're on the right track. We applaud the pharmacies and program sponsors who have come along with us on this journey to pioneer and prove a new model for pharmacy delivered services across Australia - and encourage others to join their colleagues in this national effort to demonstrate the profound and positive impact pharmacists can have in improving patient care outcomes," added Mr. Sclavos.

About Mirixa

Mirixa Corporation, sponsored by the National Community Pharmacists Association (NCPA), is the leader in targeted patient care services delivered via the nation's largest pharmacy-based patient care network. Dedicated to improving patients' health, Mirixa enables the healthcare community to deliver patient care services through retail pharmacy. The MirixaPro(SM) web-based clinical platform is used by pharmacists to deliver standardized patient care services. For more information, please visit www.Mirixa.com.

About The Pharmacy Guild of Australia

The Pharmacy Guild of Australia was established in 1928, bringing together several small retail pharmacy organizations then operating in the various States. Its members are owners of some 4,500 pharmacies throughout Australia. The development of policy is the responsibility of the Guild's supreme governing body, the National Council, on which all State and Territory Branches are represented. Implementation of policy is overseen by the National Executive and effected through the National Secretariat. For more information please visit www.guild.org.au.

    Contacts:  Christine Ryba           Ross Gallagher
               703.865.2041             011 61 2 9744 4444
               PR@Mirixa.com            rgallagher@Mirixa.com.au

SOURCE Mirixa Corporation


'/>"/>
SOURCE Mirixa Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Mirixa Corporation Announces MirixaEdge(SM)
2. Mirixa Corporation Announces Key Pharmacy Network Hire
3. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
4. New Australian Drug Holds Hope of Major Breakthrough in Treating Terminal Blood Cancers
5. S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis
6. ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia
7. Cepheid GeneXpert(R) System and Xpert(TM) MRSA Selected for up to 11 Victoria, Australia Hospitals in Rollout of Start Clean Strategy
8. New Australian Technology: Detecting Breast Cancer With Hair
9. MedImmune Advances Asthma Program with Start of a Phase 2 Trial in Europe and Australia and First U.S.-Based Clinical Trial for Antibody Targeting IL-13
10. Kibow Biotech Obtains Australian, Chinese and Indian Patents Protecting the Composition and Basic Technology Behind Its Oral Probiotic Formulation for Chronic Kidney Failure
11. PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... 5, 2017  In response to the nationwide ... Maxillofacial Surgeons (AAOMS) released prescribing recommendations that urge ... used as a first-line therapy to manage a ... Recognizing the value and importance ... "Opioid Prescribing: Acute and Postoperative Pain Management" stresses ...
(Date:10/4/2017)... LAWRENCE, Mass. , Oct. 4, 2017 /PRNewswire/ ... developer of single-use, self-contained, illuminating medical devices, today ... National Health Surveillance Agency (or Agência Nacional ... ®. The first single-use, cordless surgical retractor with ... ONETRAC provides optimal access, illumination and exposure of ...
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and ... of published author, William Nowers. Captain Nowers and his wife, Millie, have six ... years in the Navy. Following his career as a naval aviator and carrier ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
Breaking Medicine News(10 mins):